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ABSTRACT

A method is provided for detecting an analyte indicative of a
cancer or a metastatic disease condition, which utilizes the

ability of the analyte to induce permeability in a barrier. The
method includes providing a biosensor having a barrier which
is substantially impermeable to an ion, a permeable mem
brane which is selective for the ion, and a detector capable of
detecting the ion. The biosensor is contacted with a sample
including at least one of the ion and the analyte, wherein the
analyte causes at least a portion of the ion to pass through the

barrier and the membrane. Passage of the ion through the
barrier and membrane allows detection of the ion, providing
indirect detection of the analyte. In one embodiment, the
barrier is a cell monolayer, the membrane is selective for

potassium, and the analyte is vascular endothelial cell growth
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METHODS FOR CANCER DETECTION

induction of permeability in the cell portion of the biosensor
to detect and quantitate the cytokine.

This application claims the bene?t of Provisional Patent
Application Ser. No. 60/625,875 ?led on Nov. 8, 2004, the
disclosure of Which is incorporated herein in its entirety by
reference.

SUMMARY OF THE INVENTION

In accordance With the purposes of the present invention as
described herein, in one aspect of the invention a method is
provided for detecting an analyte indicative of a cancer or a

TECHNICAL FIELD

metastatic disease condition, comprising providing a biosen
sor comprising a barrier Which is substantially impermeable

The present invention relates to methods for early detection

of cancer, and for monitoring progression, metastasis, and/or

to an ion, a permeable membrane Which is selective for the

treatment ef?cacy of cancer. In particular, the invention pro
vides a method for detection of cancer comprising detection
of analytes indicative of cancer or a metastatic disease using

ion, and a detector capable of detecting the ion. The biosensor
is contacted With a sample including at least one of the ion and
an analyte indicative of a cancer or a metastatic disease con

a biosensor.

dition, Wherein the analyte causes at least a portion of the ion
to pass through the barrier and the membrane to alloW detec
tion of the presence or absence of the ion and thereby indirect
detection of the presence or absence of the analyte.
The barrier is a live cell layer knoWn to be responsive to the

BACKGROUND OF THE INVENTION

It is knoWn that early detection of cancer is highly corre

lated With patient survival. Accordingly, research has focused
on the discovery and recognition of neW diagnostic biomar

20

subsequent progression. Certain biomarkers are speci?c to
certain cancer types, i.e., prostate speci?c antigen as a diag
nostic marker for prostate cancer. HoWever, other, non-spe
ci?c biomarkers have value in early detection of cancer, deter
mination of prognosis, monitoring of effectiveness of cancer

25

measurable signal upon detection of the ion.
30

elevated concentrations at the onset of cancer and during
metastasis of cancer.

disease condition, or of the e?icacy of a treatment therefor.

The analyte may be selected from the group of cancer-related

tor (VEGF), also called vascular permeability factor (VPF).
35

mitogen, and is knoWn to be present in very small quantities

40

to its critical role in angiogenesis. During angiogenesis, neW
blood vessels form from existing vessels to supply nutrients
to the developing tumor cells. Due to VEGF’s mitogenic
nature, it facilitates the formation of the neW blood vessels by
selective action on endothelial cells.

analytes consisting of cytokines, groWth factors, hormones,
chemokines, and toxins, including but not limited to tumor

necrosis factor, basic ?broblast groWth factor, interleukin 6,
interleukin 8, hepatocyte groWth factor, or any permeability
modifying agent released by cancer, and combinations

in normal human blood in order to facilitate activities such as

Wound healing. In contrast, soluble VEGF is released in large

quantities by tumorigenic cells (e. g. carcinomas of the breast,
large and small intestine, pancreas, kidney, and the like) due

The analyte being detected Will typically be selected such
that the amount of the analyte in the sample is indicative of the
presence, progression, or severity of a cancer or a metastatic

One such cytokine is vascular endothelial cell groWth fac
Vascular endothelial cell groWth factor is an endothelial cell

the analyte is VEGF. The cell barrier is typically provided as
a substantially con?uent cell monolayer Which is contiguous
With the permeable membrane. In use, the cell monolayer is
substantially impermeable to the ion, but becomes at least
partially permeable to the ion upon contact With the analyte.
The detector may be coupled to a transducer to provide a

treatment, detection of recurrence post-treatment, and the

like. In this respect, it is knoWn that various cytokines, groWth
factors, toxins, chemokines, and hormones are found in

analyte being detected. In one embodiment of the invention,
the barrier is a transformed human endothelial cell line, and

kers that relate to the presence of cancer, its severity, and its

thereof. In one embodiment, the analyte detected is VEGF.
The membrane of the biosensor may be selected to be
natively selective for the ion of choice, or may be chemically

modi?ed for selectivity for the ion. The permeable membrane
may be chemically modifyied using an ionophore to induce
45

Quantities of VEGF in serum and plasma of patients With

selectivity for the ion. In one embodiment, a permeable cel
lulose triacetate membrane is modi?ed With valinomycin to

induce selectivity for potassium.

tumors from a multitude of cancers (small-cell lung cancer,

primary breast cancer, non-Hodgkin’s lymphoma, prostate

In another aspect of the present invention, a method is

cancer, and the like) have been found to be signi?cantly
elevated. The concentration ofVEGF has also been correlated
With the presence of metastatic disease, disease stage in col
orectal cancer, and poor prognosis in patients With small cell

provided for monitoring the presence, progression or severity

lung cancer.
Conventional assays for cytokines such as VEGF for use in
detecting, diagnosing, or monitoring the progress or progno

50 of a cancer or a metastatic disease, or the e?icacy of a treat

ment therefor, in a patient during a predetermined time inter

val, comprising the steps of (l) obtaining a biological sample
from a patient having or at risk of having a cancer or a

metastatic disease, (2) combining the biological sample With
55

sis of cancer, or for monitoring treatment e?icacy, generally

a predetermined amount of an ion to form a mixture, (3)
contacting the mixture With a biosensor as described above,

rely on speci?c immunological assays for the protein. HoW

(4) detecting the presence or absence of an analyte Which is

ever, there is a need in the art for a more rapid screening

indicative of a cancer or a metastatic disease condition in the

method for early detection and monitoring of cancer. The

screening method should be simple, reliable, and alloW detec

mixture, Wherein the analyte causes the live cell barrier to
60

tion of indices of cancer such as VEGF and other analytes

knoWn to be produced in elevated quantities during onset,
progression, and metastasis of various cancers.
The present invention satis?es this need in the art by pro

viding methods and systems for detecting and monitoring
cancer and its progression via detection and quantitation of a
cytokine using a Whole-cell biosensor. The invention relies on

become at least partially permeable to the ion Whereby the ion
is detected by the detector, (5) correlating the amount of the
ion detected With the quantity of the analyte in the biological
sample, and (6) repeating steps 1 through 5 over time to
measure the progress of the cancer or the treatment. It Will be

65

appreciated that if the sample naturally contains a knoWn,
?xed concentration of the ion, inclusion of additional
amounts of the ion is unnecessary.

US 7,595,149 B1
4

3
The biological sample may be selected from the group

mental conditions Were (A) cells only, (B) after 8 hr exposure,
and (C) after 10 hr exposure (error bars represent SEM); and

consisting of serum, Whole blood, plasma, saliva, tears, milk,
urine, other biological/physiological ?uids, a tissue biopsy,
an organ biopsy, lymphatic ?uid, and any combination
thereof. The quantity of the analyte detected in the biological

FIG. 6 shoWs the ratio of the biosensor response obtained at
0.1 M KCl folloWing 10 hr exposure to VEGF concentrations

ranging from 0 to 1,000 pg/ml, With the data ?tted using

sample may be then correlated With the presence, progress, or
severity of the cancer or metastatic disease, or With the e?i
cacy of the treatment. The biosensor used in this method is
substantially as described above. In one embodiment, the
present method comprises use of a biosensor as described
above, comprising a human umbilical vascular endothelial
cell line groWn on a cellulose triacetate membrane chemically

TableCurve 2D v5 .01 ; also shoWn are the biosensor responses

to media aspirated from metastatic melanoma cell cultures

(1205LU) at seeding densities of 1x106, 5x105, and 1><105
cells/Well; all results are plotted against the average concen
tration ofVEGF as measured by ELISA for the same samples.
Reference Will noW be made in detail to the present pre
ferred embodiment of the invention, an example of Which is

modi?ed With valinomycin to induce potassium selectivity.

illustrated in the accompanying draWings.

The biosensor is used to detect and quantify VEGF in the

biological samples.

DETAILED DESCRIPTION OF THE INVENTION

In yet another aspect of the present invention, a system for
detecting the presence of an analyte indicative of a cancer or

a metastatic disease condition, comprising a cell-based bio
sensor, anion, and at least one standard sample containing a
predetermined quantity of an analyte indicative of a cancer or
a metastatic disease condition. In one possible embodiment,

Conventional methods of cancer detection and monitoring
often rely on detection of speci?c biomarkers Which may be
diagnostic of speci?c types of cancer. HoWever, it is knoWn
20

the cell-based biosensor comprises a monolayer of human

can be correlated to early stages of cancer, to likelihood

umbilical endothelial cells on a cellulose triacetate membrane

and/or aggressiveness of metastasis, and to e?icacy of cancer

modi?ed for potassium selectivity. The ion is potassium, and

treatment.

the analyte is VEGF. The biosensor includes an electrode
supporting the membrane, With the electrode coupled to a
transducer Which provides a signal Which can be detected
upon detection of the ion by the electrode.
It should be appreciated that the embodiments shoWn and

25

described herein are illustrations of some of the modes best
suited to carry out the invention. It Will be realiZed that the

30

invention is capable of other different embodiments and its
several details are capable of modi?cation in various, obvious
aspects all Without departing from the invention. Accord
ingly, the draWings and descriptions Will be regarded as illus

recurrence. Accordingly, a biosensor-mediated method for

early detection of cancer, or for monitoring the progress and/
or treatment e?icacy of a cancer or a metastatic disease, Was

35

even during the early stages of cancer and is released in
soluble form by tumorigenic cells due to its vital role in

angiogenesis [Ferrara (2004) Endocrine Reviews 25, 581
611; incorporated herein by reference]. Therefore, in one

BRIEF DESCRIPTION OF THE DRAWINGS

embodiment of the invention, the biosensor utiliZes the ability
40

a part of the speci?cation, illustrate several aspects of the
present invention and together With the description serve to

explain the principles of the invention. In the draWings:
FIG. 1 schematically depicts an embodiment of the biosen
sor of the present invention;
FIG. 2 shoWs the preparation of a modi?ed ion-selective

It Was considered that a method of rapid screening for such
cancer-related analytes Would be useful as a general method
of monitoring presence of cancer, effectiveness of cancer
therapy, determination of prognosis, and/ or likelihood of

developed. As an example, VEGF, a multiple-isoform glyco
protein Which is a knoWn endothelial cell mitogen, is present

trative in nature, and not as restrictive.

The accompanying draWings incorporated in and forming

that blood concentrations of various cytokines and groWth
factors, While not necessarily diagnostic of speci?c cancers,

45

of VEGF to induce permeability of a human endothelial cell
line monolayer, passage of an ion therethrough, and detection
of the ion, as an indirect detection method for the analyte.
In one embodiment, depicted in FIG. 1, the biosensor 10
utiliZed in the method of the present invention comprises a
barrier 12 Which is substantially impermeable to an ion, a
permeable membrane 14 Which is selective for the ion, and a

cellulose triacetate membrane (selective for potassium) and

detector 16 capable of detecting the ion. In the depicted

attachment of a HUVEC monolayer;
FIG. 3 shoWs the biosensor response under various condi
tions: FIG. 3a shoWs the ratio of the electrode response
obtained at 0.1 M KCl folloWing treatment to the response for
the membrane Without cells or VEGF at 0.1 M KCl. Experi

embodiment, the barrier 12 is a human umbilical vein endot
helial cell monolayer coupled to an ion-selective cellulose
triacetate membrane 14 by a linker molecule 18. The barrier
12/membrane 14 complex is carried by the detector 16 to

mental conditions Were (A) 1 ug/ml VEGF only, (B) cells
only, (C) 1 ug/ml VEGF for 2 hr, (D) 1 ug/ml VEGF for 4 hr,
(E) 1 ug/ml VEGF for 5 hr, (F) 1 ug/ml VEGF for 6 hr (error

50

55

bars represent SEM); FIG. 3b shoWs calibration curves for the
biosensor under conditions A-F above, With the top line rep
resenting the average biosensor response Without cells or

A sample 24, contained in a receptacle 26, may be con
tacted With the biosensor 10, Wherein the sample 24 includes
at least one of the ion and an analyte of interest. It Will be

VEGF;
FIG. 4 shoWs the ratio of the biosensor response folloWing

provide an ion-selective electrode 20 as Will be described in
greater detail beloW. A reference electrode 22 may also be
provided as part of the detector 16 as is knoWn in this art to
alloW detection of a potentiometric difference in response to
detection of the ion.

60

appreciated that the analyte Will typically be indicative of a
cancer and/or a metastatic disease condition, and further
causes at least a portion of the ion to pass through the barrier

exposure to 100 ng/ml VEGF to the response for the bio sensor
Without cells or VEGF. Experimental conditions Were (A)

cells only, (B) after 6 hr exposure, and (C) after 8 hr exposure

12 and the permeable membrane 14 to be detected by the

(error bars represent SEM);

detector 16.

FIG. 5 shoWs the ratio of the biosensor response obtained at
0.1 M KCl folloWing exposure to 1 ng/ml VEGF to the
response for the biosensor Without cells or VEGF. Experi

65

The folloWing examples are presented in support of and to
further illustrate the invention as described herein. HoWever,
the invention is not to be considered as limited thereto.

US 7,595,149 B1
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Example 1

outer compartment. Potentiometric responses Were measured

With a four-channel high impedance ampli?er interface
Referring to FIG. 2, a cellulose triacetate (CTA; Eastman
Kodak, Rochester, NY.) membrane Was prepared as an ion
selective support for a cell layer. The base layer of the mem
brane Was prepared by dissolving 74 mg of CTA pellets in 1.1

(World Precision Instruments) connected to a Model 100
1nstrunet A/ D converter. Data Were analyzed using 1nstrunet
softWare on a Macintosh PoWer PC. Prior to initial use, the
electrodes Were conditioned in sterile 0.1 M KCl solution.

Calibration plots Were constructed by plotting the measured
potential (mV) versus the logarithm of the concentration of
potassium ions present in the bulk solution.

mL of methylene chloride (Aldrich, Milwaukee, Wis.), 0.4
mL of chloroform (Aldrich), and 0.40 mL of 1,1,2,2-tetra
chloroethane (Aldrich). The mixed solution Was then cast in a

31 mm id. glass ring placed on a TEFLON plate. After
solvent evaporation, the membrane Was removed and ?oated
on 1.0 M sodium hydroxide for 4.5 hr. Raised edges of the
membrane ensured that only the loWer surface of the mem
brane Was hydrolyzed to provide free OH groups. The mem

Example 2
The response of the biosensor as described in Example 1
Was ?rst evaluated after protein immobilization and as a func

tion of cell con?uency. After con?rmation of the inhibited
response folloWing 24 h of cell groWth (i.e., diminished trans

brane Was then rinsed With deionized Water.

A second membrane layer Was cast using an ionophore

cocktail to induce selectivity for potassium. The ionophore
cocktail consisted of 1 mg of valinomycin (Calbiochem, San

port of potassium through the con?uent monolayer), the cell

Diego, Calif.), a plasticizer (100 ML of o-nitrophenyl octyl
ether; Fluka, Ronkonkoma, N.Y.), and a lipophilic salt (0.42
mg potassium tetrakis(chlorophenyl)borate; Fluka) With 35

ranging from 100 pg/mL to 1 ug/mL (pH 7.0 in 0.1% BSA in
PBS) for times ranging from 2 to 10 hr. The biosensor

based membranes Were exposed to concentrations of VEGF
20

response Was measured for the folloWing conditions at a ?nal
concentration of 0.1 M. KCl: (1) membrane Without cells or
VEGF exposure to con?rm that the membrane response Was

mg of CTA. The mixture Was dissolved in a solvent mixture

composed of 0.80 mL of methylene chloride and 0.80 mL of
chloroform. The solvent Was alloWed to evaporate for 2 days
as the tWo membrane layers fused into a single asymmetric
membrane.
The bottom side of the basic membrane (having the free
OH groups) Was immersed in cold deionized Water. Next, 324

25

VEGF did not affect the response in the absence of HUVECs

(FIGS. 3a, 4, and 5); (3) membrane With cells and Without
VEGF to con?rm the inhibited sensor response after 24 h of

cell groWth (FIGS. 3a, 4, and 5); and (4) membrane With cells

mg of carbonyldiimidazole (CD1; Sigma, St. Louis, Mo.) Was
added in increments over a 15 min period, giving a ?nal
concentration of 0.10 M CD1 to activate the surface for pep

tide coupling. The membrane Was then immediately incu
bated overnight in a 0.1 M sodium carbonate solution (pH
9.5) containing 400 pg of a synthetic RGD peptide sequence
(Bachem, King of Prussia, Pa.) to promote cell binding to the
membranes. The peptide sequence used Was Gly-Arg-Gly

30

(Pierce Biotechnology, Rockford, Ill).

and With varying concentrations of VEGF at different expo
sure times. Data Were reported as a ratio of the potential

response for ion-selective electrodes (1SEs) With HUVECs
and/or VEGF to the potential response of the 1SEs Without
HUVECs or VEGF for a ?nal concentration of 0.1 M KCl to
35

account for slight variations betWeen fabricated membranes.
Three to ?ve replicates Were performed for each VEGF con
centration.
Response of the biosensor to a high concentration ofVEGF

Asp-Ser (GRGDS) to promote covalent peptide attachment
from the N-terminal amine. This is because the arg-gly-asp
(RGD) segment of ?bronectin is one of the most Widely
recognized protein sequences to Which human umbilical vein
endothelial cells (HUVECs) bind. The membranes Were then
rinsed sequentially With 0.10 M NaHCO3, deionized Water,
acetate buffer (pH 4.0), and deionized Water. Protein immo
bilization Was con?rmed using a micro-BCA protein assay

not affected by RGD; (2) membrane Without cells and With
VEGF (1 ug/mL) to con?rm that the highest concentration of

(1 ug/mL) Was evaluated. Referring to FIG. 3, no signi?cant
40

response from the sensor Was obtained at 2 and 4 hr of expo

sure. Increasing the exposure time to 5 hr signi?cantly
increased the response, and at 6 hr of exposure the response

Was nearly double that of the 5 hrresponse period. Calibration
curves for each exposure time supported these ?ndings (FIG.
45

3b).

Six mm id. disks cut from the membranes prepared as
described above Were mounted onto Philips 1S-561 electrode

It Was desired also to evaluate the loWer detection limit of
the sensor. The biosensor of Example 1 Was exposed to a

bodies (Glasblaserei Moller, Zurich) With the RGD-modi?ed

reduced concentration (100 ng/ml) of VEGF. Experimental

surface of the membrane facing the sample solution. Human
umbilical vein endothelial cells (Cambrex BioScience, East
Rutherford, N.J.) Were cultured in an EGM-2 media (Cam
brex BioScience) supplemented With fetal bovine serum,

hydrocortisone, insulin-like groWth factor, basic ?broblast
groWth factor, VEGF, human epidermal groWth factor, ascor
bic acid, human ?broblast groWth factor, gentamicin sulfate,

50

100 ng/ml of VEGF for 6 hr, but approximately tripled after 8
hr (FIG. 4). Reducing the VEGF concentration to 1 ng/ml
With an 8 hr exposure period resulted in a response ratio
55

amphotericin-B, and heparin. The HUVECs Were used
experimentally up to passage 5. The HUVECs Were seeded
onto the bottom surface of the electrode-mounted membrane
disks at a density of 1><115 cells/mL. The cells Were alloWed
to spread and form a con?uent monolayer over the membrane
surface for 24 h at 370 C. in a humidi?ed incubator With 5%

conditions Were substantially as described previously. The
response ratio Was very loW after exposing the biosensor to

nearly equal to the control response (monolayer Without
VEGF). HoWever, increasing the response time to 10 hr sig
ni?cantly increased the response ratio (FIG. 5).

Example 3
60

The response ratio from the biosensor Was evaluated as a
function of the concentration of VEGF. The sensor Was

CO2.

exposed to increasing concentrations (100, 300, and 600

The internal ?lling solution for the electrode Was 0.01 M
KCl, and the internal reference electrode Was Ag/AgCl. The
external reference electrode Was a double-junction Ag/AgCl

pg/ml) of VEGF, over a 10 hr exposure period based on the

electrode (Orion Model 90-02-00) With an Orion (90-02-02)
internal ?lling solution and 0.1 M Tris buffer (pH 7.5) in the

results described in Example 2. Referring to FIG. 6 (see the
65

plot of “Obtained sensor values”), as the concentration of
VEGF increased, the response ratio also increased. The curve

shape Was characteristic of binding events shoWing a rapid

US 7,595,149 B1
7
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binding rate at lower cytokine concentrations, and reaching

The data points for the ELISA assay fell Within the standard
errors of the plot representing the biosensor model except at
the loWest concentrations of VEGF.
VEGF concentrations determined by the biosensor method
and by ELISA are shoWn in Table 1. For the metastatic cell

saturation at higher cytokine concentrations. Based on these
data, the detection limit for the biosensor under these condi
tions Was estimated to be 70 pg/ml.

Example 4

line (l205LU) at higher cell seeding densities (l X106 and
5><l05 cells/Well), the biosensor gave results comparable to
ELISA. The biosensor substantially predicted actual VEGF

Detection of unknown concentrations of VEGF produced

by cell lines Was evaluated also. For comparison, a conven
concentrations as measured by ELISA, and Was shoWn to
tional immunoassay for VEGF Was used to detect VEGF in 10 respond to VEGF concentrations corresponding to docu
the samples. The medium Was assayed for VEGF using a
mented concentrations of VEGF found in blood of cancer

Human Quantikine VEGF ELISA kit (R & D Systems, Min
neapolis, Minn.) according to the manufacturer’s instruc

patients [Haggstrom et al. (2000) Prostate 45:42-50; Salven et
al. (1998) Cancer 79:144-146; Duque et al. (1999) Urology
tions. Samples Were analyZed at 450 nm using an El,C Univer
54: 523-527 (all incorporated herein in their entirety by refer
sal Microplate Reader (Bio-Tek Instruments) With three 15 ence)]. Table 1 also shoWs that the nonmetastatic (WM 793)

replicates per cell line. Data are reported as mean concentra

tion (pg/ml):SEM. Tu2% medium and MelM medium (see

cells produced no detectable VEGF as measured by ELISA.
Similarly, the biosensor results Were Within the range seen in

beloW) Were also assayed as controls.

the control studies (see FIGS. 3-5). By Way of con?rmation,

Human epidermal melanocytes (HEMs; ScienCell, San

normal HEMs produced no detectable VEGF by ELISA
assay, and the biosensor produced no appreciable response.

Diego, Calif.) Were cultured in MelM media (ScienCell) as

TABLE 1
Comparison of in vitro VEGF production by various cell types.

Seeding
density
1205LU

WM793

HEMs
TU2%
MelM
HUVEC
0.1
W/v %
BSA in
PBS

(cells/Well)

Final
concentration
(cells/ml)

ELISA
concentration
(pg/ml)

1><106
5 ><105
1><105
1><106

1.1><106
4.2 ><105
2.4 ><105
9.2 ><105

387 1 25
220 115
17.4 1 3 7
ND

5 ><105

4.0 ><105

ND

0.04 1 0.01

0
0

1><105
1><105
N/A
N/A
N/A
N/A

2.1 X 105
5.3 ><105
N/A
N/A
N/A
N/A

ND
ND
ND
ND
NM
NM

0.05 1 0.02
0.04 1 0
0.04
0.05
0.05
0.04

0
0
0
0
0
0

Response ratio
from biosensor
0.32
0.27
0.08
0.03

1
1
1
1

0.02
0.02
0
0.01

Predicted
concentration from
sensor (pg/ml)
339 1 80
189 1 54
0.86 1 0.4

Data presented as means 1 SEM.
ND = not detectable.
NM = not measured.

Accordingly, it has been shoWn that the biosensor of the
controls. Subculturing reagents Were trypsin/EDTA, TNS, 45
and PBS. WM793 nonmetastatic melanoma cells (not
present invention has a detection limit of at least 70 pg/ml.

expected to produce signi?cant quantities of VEGF) and

Using the molecular Weight of VEGF165 (42 kDa), this cor

l205LU metastatic melanoma cells (expected to produce
responds to a 2x10‘12 M detection limit. The biosensor can
VEGF) Were obtained from the laboratory of Dr. David Kaet
therefore be used to effectively screen for quantities ofVEGF
Zel, University of Kentucky. These cells Were cultured in 50
in biological samples, such as for example blood samples,
TU2% medium consising of MCDB 153 medium poWder

from cancer patients. Since it is knoWn that VEGF levels in
biological samples, including serum and plasma, are corre
lated With the presence, metastasis, and disease stage of can
ate, and calcium chloride. Subculturing reagents Were
trypsin/EDTA and PBS.
55 cer (Haggstrom et al., 2000; Salven et al., 1998; Duque et al.,
The cell lines Were cultured for 48 hr (groWth) in test Wells
1999), the biosensor of the present invention can be used to
at various densities, and supernatant Was WithdraWn. Initial
effectively screen for cancer.
cell density Was controlled in each test Well, and the ?nal cell
In comparison to conventional screening procedures such

(Sigma), LeibovitZ’s L-l5 medium poWder (Gibco, Invitro
gen Corp.), FBS (Sigma), bovine insulin, sodium bicarbon

count Was determined to con?rm that the groWth rate of the
as biopsies, the method of the present invention is adaptable
cells Was consistent over the 48 hr period. After 48 hr of 60
for use in a minimally invasive manner, and could be used as
groWth, the biosensor Was exposed to the supernatant

medium for 10 hr as described in Example 4.
Concurrently, a VEGF ELI SA Was performed on the same

an early cancer screening tool by a physician during a routine
o?ice visit. Further, the method of the present invention pro
vides the further advantage of a rapid response time (10 hr or

supernatant medium samples. The ELISA results for the
l205LU (metastatic) cells Were plotted against the biosensor 65 less), in comparison to a conventional biopsy procedure,
Which may take a Week or more to schedule, perform the
response ratio (FIG. 6) to evaluate hoW closely the biosensor
predicted the VEGF concentration as measured by ELISA.
procedure, and report the results to the patient.
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The foregoing description of the preferred embodiment of

What is claimed is:

this invention has been presented for purposes of illustration

1. A method for detecting an analyte, comprising:

and description. It is not intended to be exhaustive or to limit

providing a biosensor comprising a live endothelial or epi

thelial cell barrier Which is substantially impermeable to
a potassium ion, a permeable membrane Which is selec
tive for the potassium ion, and a detector capable of

the invention to the precise form disclosed. Obvious modi?
cations or variations are possible in light of the above teach

ings. It Will be appreciated by the skilled artisan that the

detecting the potassium ion;

method may be adapted to a variety of combinations of cell

types, analytes, and ions used in the biosensor, With the pro
viso that the analyte or analytes be indicative or predictive of
a cancer, and that permeability is induced in the particular cell
type used. For example, different cell types could be incor
porated into the biosensor of the invention, either alone or in
combination, such as native endothelial cells, keratinocytes,

contacting the biosensor With a sample including at least

lung cells, kidney cells, and the like, With the proviso that the

portion of the potassium ion to pass through the live cell
barrier and the membrane; and
detecting the presence or absence of the potassium ion.

one of the potassium ion and an analyte selected from at
least one of a vascular endothelial groWth factor, a basic

?broblast groWth factor, a hepatocyte groWth factor, and
a tumor necrosis factor-0t, Wherein the analyte induces
permeability of the live cell barrier and causes at least a

cells form a layer that is substantially impervious to passage
of the ion of choice absent contact With a permeability-induc

ing analyte.
Alternative membrane types are also contemplated by the
present invention, including polymer membranes such as

polyurethane, poly-(hydroxyethyl)methacrylate, poly(vinyl)

20

2. The method of claim 1, Wherein the live cell barrier is a
transformed human endothelial cell line.
3. The method of claim 2, Wherein the live cell barrier is
provided as a substantially con?uent cell monolayer Which is

chloride, and the like, Which may be utiliZed in order to
improve cell adhesion or alter the mechanism of attachment

contiguous With the permeable membrane.

of the bridging linker, With the proviso that the membrane is

substantially impermeable to the potassium ion, and becomes

4. The method of claim 3, Wherein the cell monolayer is

or can be made selective for the ion of choice.

Still further, it Will be appreciated that the detected mol

25

detector to a transducer providing a measurable signal.
6. The method of claim 1, Wherein the analyte is a vascular

ecule need not be an ion, but may be any ionic or neutral

molecule, With the proviso that the sensor is able to detect the
molecule and the membrane is appropriately selective for the
molecule.

Still yet further, multiple biosensors comprising different
cell types and membrane types, each being more or less
sensitive to the presence of a particular cancer-inducing ana
lyte, may be incorporated into a sensor array adapted for
detection of multiple combinations of analytes, such as for
example a combination of VEGF, tumor necrosis factor, and

endothelial groWth factor.
7. The method of claim 1, including the step of chemically
30

modifying a permeable cellulose triacetate membrane to

induce selectivity for the potassium ion.
8. The method of claim 7, including chemically modifying
the cellulose triacetate membrane With valinomycin to induce

selectivity for potassium.
35

9. A method for monitoring an analyte in a patient during a

predetermined time interval, comprising:

interleukin 8, to facilitate complete sample analysis and
improve the predictive value of the method.

(1) obtaining a biological sample from a patient;
(2) combining the biological sample With a predetermined

The embodiment Was chosen and described to provide the

best illustration of the principles of the invention and its
practical application to thereby enable one of ordinary skill in

at least partially permeable upon contact With the analyte.
5. The method of claim 1, including the step of coupling the

amount of a potassium ion to form a mixture; and
40

(3) contacting the mixture With a biosensor comprising: (a)
a live endothelial or epithelial cell barrier Which is sub

the art to utiliZe the invention in various embodiments and
With various modi?cations as are suited to the particular use

stantially impermeable to the potassium ion, (b) a per

contemplated. All such modi?cations and variations are
Within the scope of the invention as determined by the

meable membrane Which is selective for the potassium

appended claims When interpreted in accordance With the
breadth to Which they are fairly, legally, and equitably

45

entitled.

SEQUENCE LISTING

SEQ ID NO 1
LENGTH: 5
TYPE: PRT

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION:

<400> SEQUENCE: 1

Gly Arg Gly Asp Ser
1

5

synthetic RGD peptide sequence

ion, and (c) a detector capable of detecting the potassium
ion;

(4) detecting the presence or absence in the mixture of an
analyte selected from at least one of a vascular endothe
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11. The method of claim 9, wherein the live cell barrier
comprises a transformed human endothelial cell line.

lial growth factor, a basic ?broblast growth factor, a
hepatocyte growth factor, and a tumor necrosis factor-0t,
wherein the analyte causes the live cell barrier to become

12. The method of claim 11, including providing the live

at least partially permeable to the potassium ion
whereby the potassium ion passes through the live cell
barrier and the membrane and is detected by the detec
tor;
(5) correlating the amount of the potassium ion detected
with the quantity of the analyte in the biological sample;

cell barrier as a substantially con?uent monolayer which is
5

to a transducer providing a detectable signal.
14. The method of claim 9, wherein the analyte is a vascular

endothelial cell growth factor.
15. The method of claim 9, including the step of chemically

and

(6) repeating steps 1 trough 5 after a predetermined time
interval has passed.
10. The method of claim 9, including selecting the biologi
cal sample from the group consisting of serum, whole blood,
plasma, a tissue biopsy, an organ biopsy, lymphatic ?uid,
saliva, tears, milk, urine, and any combination thereof.

contiguous with the permeable membrane.
13. The method of claim 9, including coupling the detector

modifying a permeable cellulose triacetate membrane to

15

induce selectivity for the potassium ion.
16. The method of claim 15, including chemically modi
fying the cellulose triacetate membrane with valinomycin to
induce selectivity for potassium.
*

*

*

*
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